News & Media
Novavax to Showcase Innovative Vaccine Data at Communicable Diseases & Immunisation Conference 2022
Jun 17, 2022

Novavax will present encore safety and immunogenicity data from its COVID-19 vaccine (NVX-CoV2373) trials, as well as encore safety and efficacy data on the Novavax Influenza vaccine candidate at the Communicable Diseases & Immunisation Conference (CDIC) 2022 in Sydney, Australia, from June 20 to 22, 2022. Data will be presented during six oral presentations at the conference.

Novavax presentations during CDIC:

Toback, S

Ongoing Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine in the United Kingdom

Oral (encore)

Monday, June 20, 2022

1:30 PM - 3:00 PM AEST

Shinde, V

Phase 3 trial of a SARS-CoV-2 Protein Vaccine (NVX-CoV2373) in Adolescents (PREVENT-19)

Oral (encore)

Monday, June 20, 2022

1:30 PM - 3:00 PM AEST

Beyhaghi, H

Reported Pregnancies and Associated Outcomes Across the Novavax COVID-19 Vaccine Clinical Program

Oral (encore)

Monday, June 20, 2022

3:30 PM - 5:00 PM AEST

Marchese, A

COVID-19 Vaccine Receptivity and Preferences among Vaccine Hesitant Individuals

Oral (encore)

Monday, June 20, 2022

3:30 PM - 5:00 PM AEST

Toback, S

The Safety and Efficacy of NVX-CoV2373 Co-administered With Seasonal Influenza Vaccine

Oral (encore)

Tuesday, June 21, 2022

1:30 PM - 3:00 PM AEST

Shinde, V

Long-term polyfunctional CD4+ T-cell responses after recombinant hemagglutinin saponin-adjuvanted nanoparticle influenza vaccination

Oral (encore)

Tuesday, June 21, 2022

1:30 PM - 3:00 PM AEST